£2.5m of Government funding to accelerate delivery of Incubator at Discovery Park
Science Park helping to drive local economic growth with SELEP support
Sandwich, Kent, August 4 2020 – Discovery Park, the Life Sciences Opportunity Zone for ambitious and growing life sciences companies, has been awarded £2.5m towards accelerated delivery of its Incubator facility by the South East Local Enterprise Partnership (SELEP). The grant, which comes from SELEP’s £85m share of the Government’s new Getting Building Fund, will be used to create flexible laboratory, write-up and office space for…
Situation:
The coronavirus (COVID-19) pandemic has presented an enormous challenge to individuals and organisations worldwide. Adapting to living with the threat of the SARS-CoV-2 virus among our communities has required significant changes in how we behave and operate.
Our position:
At Richmond Research Institute (RRI), as a not-for-profit clinical research organisation focused on medicines and patient safety, we were acutely aware we had access to resources and expertise we could re-deploy to start COVID-19 testing quickly. Originally born out of the necessity to protect and enable…
Where next for UK life sciences regulation?, Where next for the EU’s pharmaceutical strategy? International data transfers after the demise of the US Privacy Shield, Supply chain resilience, and much more…..
Sequence - July 2020 - Issue 11
- AlmirallShare launches its fifth call for proposals, aiming to establish partnerships to find new assets—new chemical entities, biologics and other advanced therapies—for the treatment of dermatological conditions
- Scientists can participate until October 31, 2020
- AlmirallShare is responsible for 50% of the private-public collaborations at Almirall. This open innovation platform has received more than 350 proposals since its launch in 2017
AlmirallShare, the open innovation platform of Almirall, S.A. (ALM), launches its fifth call, aiming to establish collaborations in dermatological…
AMSBIO offers a comprehensive range of end-to-end services for exosome purification, characterization, and engineering.Exosomes are small endosome derived lipid nanoparticles, actively secreted by exocytosis in most living cells. Acting on tissues in both the local environment and further afield, they function as important signal carriers through their transport of RNA, proteins, lipids and DNA. Exosomes are involved in a wide range of normal and pathogenic processes, making exosome research crucial in multiple areas. Exosomes are a type of extracellular vesicle (EV) that show promise…
With the expansion of two of Biocair’s North American facilities, the company’s offerings in the US have increased substantially.
The Philadelphia office has doubled in size, with a state-of-the-art cryogenic filling station to further support cell and gene therapy clients, while the expanded Boston office will allow Biocair to improve delivery and service, with greater operational capacity.
Bruce Kennedy, Chief Commercial Officer, stated, “Biocair has always been strong in the US market, with offices in Los Angeles, New York, Raleigh Durham, San Diego, San Francisco and Washington as well as…
Cambridge, UK, 29 July 2020: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or “the Company”), a cell engineering company focused on commercialising the application of gene editing and gene modulation to accelerate scientific innovation and biopharmaceutical drug development, today provides an unaudited pre-close trading update for the six months ended 30 June 2020. The Company plans to report its half year 2020 results on 17 August 2020.
Financials
Horizon expects to report half year 2020 revenues of approximately £22.4 million (HY 2019: £26.1 million, c. -13.9%)1,…
Westbury, NY – July 28, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it can now provide broader access to its growing inventory of plasma, serum and saliva specimens from active and recovered COVID-19 patients for use in drug, diagnostic and vaccine research.
“COVID-19 has already afflicted more than 16 million people and claimed more than 650,000 lives worldwide. It is a complex disease that demands the attention of the world’s best medical researchers. We are already working with more than 500 clients,…
Launched in 2018, Kao Data develop and operate advanced data centres for high performance computing. From our hyperscale inspired campus in the heart of the UK Innovation Corridor between London and Cambridge - we provide HPC, cloud, AI and enterprise customers with a world-class home for their compute.
We are proud to be sponsoring the Start-up of the Year Award at the 2020 Cambridge Independent Science and Technology Awards.
Spencer Lamb, vice president at Kao Data, says: “At Kao Data, we provide the infrastructure that underpins innovation – and so we are especially proud to be sponsoring…